Bausch + Lomb Highlights Surgical, Pharmaceuticals and Consumer Health Care Innovations at AAO 2020 Virtual Meeting

Bausch + Lomb announced plans to highlight its latest surgical, pharmaceuticals and consumer health care innovations, as well as several new business ventures, at the company’s virtual exhibit booth during the annual meeting of the American Academy of Ophthalmology (AAO), which takes place Nov. 13-15, 2020. The company also will offer attendees the opportunity to participate in a variety of Industry Showcase presentations, during which prominent surgeons will discuss topics such as postoperative case management, phacodynamics, glaucoma, and vitreoretinal surgery.

“We are proud of the progress that we have made this year, and the resolve that the entire eye care community has demonstrated, despite the many challenges that we’ve encountered,” Joe Gordon, U.S. president, Bausch + Lomb, said in a company news release. “We look forward to the opportunity to update our customers about these developments, and provide them with educational opportunities, both of which we believe will help them better serve their patients, now and in the future.”

Innovations Featured in Booth

Launched in October, the SimplifEYE IOL delivery system is exclusively available for the enVista MX60PL and the enVista toric MX60PT, the first preloaded toric IOL available in the United States. This new system facilitates smooth and consistent implantation of enVista lenses in just three steps through an incision as small as 2.2 mm.

New additions to the retina portfolio include the 27-gauge endoilluminator, which is 156% more rigid and 20% brighter than the previous 25-gauge design. These improvements allow the user to confidently manipulate the endoilluminator while facilitating improved access and visualization of the periphery during retina surgery.

Attendees are invited to visit the Bausch + Lomb virtual booth for more details on these products as well as the rest of the company’s broad offering of surgical technologies, including the Victus femtosecond laser platform, the Stellaris Elite vision enhancement system, as well as the enVista, Crystalens and Trulign families of IOLs.

The company’s proprietary pharmaceutical products will also be featured in the booth. These include Bepreve (bepotastine besilate ophthalmic solution) 1.5%, Besivance(besifloxacin ophthalmic suspension) 0.6%, Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, Istalol(timolol maleate ophthalmic solution) 0.5%, Lacrisert (hydroxypropyl cellulose ophthalmic insert), Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg, Prolensa(bromfenac ophthalmic solution) 0.07% and Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

PreserVision AREDS 2 Formula eye vitamins, which are from the company’s consumer health care division, will also be highlighted in the booth. PreserVision is the most studied eye vitamin brand based on the AREDS and AREDS2 clinical studies conducted by the National Eye Institute (NEI). These vitamins contain the exact nutrient formula recommended by the NEI to help reduce the risk of moderate to advanced age-related macular degeneration (AMD) progression.

Business Development News

Earlier this year, Bausch + Lomb signed an exclusive licensing agreement with STADA and its development partner, Xbrane, to develop and commercialize, if approved, a biosimilar candidate to Lucentis (ranibizumab) in the United States and Canada.

In September, Bausch + Lomb announced that it had entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics. This agreement could significantly enhance the company’s comprehensive portfolio of products, particularly for AMD.

The company also recently received an exclusive license to Eyenovia’s investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12. This investigational formulation of atropine is delivered with Eyenovia’s Optejet dispenser technology and, if approved, would be another important step forward in the company’s progress to finding treatments to meet the needs of myopia patients.

Industry Showcase Presentations

Virtual Industry Showcase presentations hosted by Bausch + Lomb will include:

Friday, Nov. 13:

• “Expert Post-Operative Case Management During Uncertain Times” presented by Paul Singh, MD, at 8:45 a.m. PT (session #: ISC02).
• “Clinical Glaucoma Management During the COVID-19 Pandemic” presented by Shan Lin, MD, at 2:40 p.m. PT (session #: ISC08).

Saturday, Nov. 14:

• “Bi-Blade Dual-Port Technology: Advancing Efficiency & Stability in Vitreoretinal Surgery” presented by Sunir Garg, MD, and Rahul Reddy, MD, at 6 a.m. PT (session #: ISC13).
• “Astigmatism Correction with enVista Toric: SimplifEYE’d” presented by Mitchell Shultz, MD, and Marjan Farid, MD, at 1 a.m. PT (session #: ISC20).

Sunday, Nov. 15:

• “Can Your Femto Do This? A Focus on VICTUS Corneal Work” presented by Michael J. Endl, MD, and Thomas R. Elmer, Jr., MD, at 6 a.m. PT (session #: ISC65).
• “Understanding Phacodynamics: Misconceptions vs. Facts” presented by Barry S. Siebel, MD, and Timothy P. Page, MD, at 2:05 p.m. PT (session #: ISC35).